PTAB upholds key Seer (Nasdaq: SEER) Proteograph patent claims

Rhea-AI Filing Summary

Seer, Inc. reported that the U.S. Patent Trial and Appeal Board issued a Final Written Decision in an inter partes review of U.S. Patent No. 11,435,360 B2 covering Seer’s nanoparticle-based protein enrichment technology for its Proteograph product suite.

The PTAB found that petitioners PreOmics GmbH and Biognosys AG failed to show unpatentability of certain challenged claims, leaving a total of 23 patent claims, including five challenged and 18 unchallenged, valid and enforceable. Other challenged claims were found unpatentable. The upheld claims relate to detecting proteins across a wide concentration range and to particle aspects of the technology, which support deep proteomic analysis. Either side may appeal by filing a notice of appeal by May 25, 2026.

Insights

Life sciences IP and litigation analyst

PTAB leaves most key Seer patent claims intact, preserving core Proteograph IP while invalidating some claims.

The decision confirms that 23 claims of U.S. Patent No. 11,435,360 remain valid, including challenged claims tied to protein detection range and nanoparticle design. These elements are described as underpinning Seer’s Proteograph platform for deep proteomic analysis.

Some other challenged claims were found unpatentable, so competitive risk depends on which claim scopes competitors may now navigate around. However, Seer highlights a broader portfolio of more than 240 issued patents and pending applications worldwide, including 80 issued patents, which may mitigate exposure if future disputes arise.

Appeal rights run until May 25, 2026, so the legal landscape could evolve if either side challenges the ruling. Subsequent court or PTAB proceedings, if pursued, would further define the long‑term strength and breadth of Seer’s IP position around its Proteograph product suite.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Valid patent claims: 23 claims Total patent claims: 29 claims Challenged claims: 11 claims +3 more

6 metrics

Valid patent claims 23 claims Claims of U.S. Patent No. 11,435,360 remaining valid after PTAB review

Total patent claims 29 claims Total claims in U.S. Patent No. 11,435,360 referenced in the review

Challenged claims 11 claims Number of patent claims challenged in inter partes review IPR2024-01473

Appeal deadline May 25, 2026 Last date for parties to file notice of appeal of PTAB decision

IP portfolio size more than 240 patents and applications Worldwide portfolio of issued patents and pending applications cited by Seer

Issued patents 80 issued patents Part of Seer’s stated global intellectual property portfolio

Key Terms

inter partes review, Final Written Decision, protein coronas, Proteograph Product Suite, +2 more

6 terms

inter partes review regulatory

"issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2"

An inter partes review is a formal proceeding at the U.S. Patent Office where a third party asks a panel to re-examine and possibly cancel all or part of an issued patent based on earlier public information. Investors care because the outcome can remove or uphold a company’s exclusive rights, directly affecting product exclusivity, potential revenue, legal exposure and the valuation of businesses that rely on that patent—like asking a neutral referee to re-check a key call in a game.

Final Written Decision regulatory

"the Patent Trial and Appeal Board issued a Final Written Decision on March 23, 2026"

protein coronas technical

"engineered nano- and microparticles that form protein coronas, resulting in protein enrichment"

Protein coronas are layers of blood or tissue proteins that stick to the surface of tiny drug carriers or diagnostic particles when they enter the body, effectively giving the particle a new biological “coat.” This coat can change how the particle is seen by the immune system, where it travels, how long it lasts, and whether it works as intended, so investors watch protein coronas because they affect a product’s safety, effectiveness, and regulatory approval risk.

Proteograph Product Suite technical

"23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph Product Suite"

forward-looking statements regulatory

"This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

0001726445false00017264452026-03-232026-03-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 23, 2026

Seer, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39747		82-1153150
(State or other jurisdiction of		(Commission		(I.R.S. Employer
incorporation)		File Number)		Identification No.)

3800 Bridge Parkway, Suite 102

Redwood City, California 94065

(Address of principal executive offices, including zip code)

650-453-0000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share	SEER	The NASDAQ Stock Market LLC (The NASDAQ Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 30, 2026, Seer, Inc. announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2. The inter partes review (IPR2024-01473) was filed by PreOmics GmbH and Biognosys AG, challenging claims 1-4, 6, 7, 17, and 22-25 of the ‘360 patent. In its Final Written Decision, the PTAB determined that the petitioners failed to demonstrate the unpatentability of claims 2, 3, 7, 23, and 24 of the ‘360 patent, resulting in a total of 23 claims, the five upheld and another 18 unchallenged, remaining valid and enforceable. The upheld claims include limitations relating to the depth and dynamic range of proteins detected by the claimed methods and the nature of the particles used in the methods. The PTAB determined that claims 1, 4, 6, 22, 24, and 25 were unpatentable.

Either party choosing to pursue appeal must file a notice of appeal by May 25, 2026.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release dated March 30, 2026, titled “Seer's Particle Proteomics Patent Stands After Challenge by Bruker Subsidiaries.”
104		Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SEER, INC.
Date: March 30, 2026		By:		/s/ David Horn
				David Horn
				President and Chief Financial Officer

Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries

23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite

REDWOOD CITY, Calif., March 30, 2026 — Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the “’360 Patent”). The inter partes review was filed by PreOmics GmbH and Biognosys AG, each a subsidiary of Bruker Corporation, challenging 11 of 29 claims of the ’360 Patent.

The ’360 Patent covers methods for analyzing biological samples using engineered nano- and microparticles that form protein coronas, resulting in protein enrichment that underlies Seer’s Proteograph platform for deep proteomic analysis. The ’360 Patent is owned by The Brigham and Women’s Hospital, Inc. and is exclusively licensed to Seer.

A total of 23 claims, including five challenged claims and 18 unchallenged claims, remain valid and protect Seer’s nanoparticle protein enrichment technology for analyzing biological samples, including cells, tissues and biofluids. The upheld claims are directed to detecting proteins across a wide concentration range and to particle-related aspects of Seer’s technology, both of which enable deep proteomic analysis.

“The PTAB’s decision affirms the strength of our technology and our Proteograph platform,” said Omid Farokhzad, Chair and Chief Executive Officer of Seer. “Seer pioneered the Proteograph platform, and our approach enables the deep, reproducible, and scalable proteomics data our customers depend on. We will continue to defend and invest in the IP that protects our technology and makes it possible for us to continue bringing exceptional insights to our customers.”

Seer’s Proteograph Product Suite integrates proprietary engineered nanoparticles, automation instrumentation, and analytical software to enable deep, unbiased proteomics at scale. The platform is supported by an intellectual property portfolio of more than 240 issued patents and pending patent applications worldwide, including 80 issued patents.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer's Proteograph Product Suite integrates proprietary engineered nanoparticles, automation instrumentation, optimized consumables, and advanced analytical software. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the strength and scope of Seer's intellectual property portfolio, Seer's ability to protect its innovations and market position, and the company's plans to pursue available legal options. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission ("SEC") and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:

Patrick Schmidt
pr@seer.bio

Investor Contact:

Marissa Bych or Connor O’Neill
investor@seer.bio

FAQ

What did the PTAB decide about Seer (SEER) Patent No. 11,435,360?

The PTAB issued a Final Written Decision upholding 23 claims of U.S. Patent No. 11,435,360. These include five challenged and 18 unchallenged claims that protect Seer’s nanoparticle-based protein enrichment methods supporting its Proteograph proteomics platform.

Who challenged Seer (SEER)’s ’360 patent and what claims were at issue?

PreOmics GmbH and Biognosys AG, both subsidiaries of Bruker Corporation, filed the inter partes review. They challenged 11 of 29 claims of U.S. Patent No. 11,435,360, targeting specific method and particle-related aspects of Seer’s protein enrichment technology.

How many claims of Seer (SEER)’s ’360 patent remain valid after the PTAB review?

A total of 23 claims of U.S. Patent No. 11,435,360 remain valid and enforceable. This includes five challenged claims that survived the inter partes review and 18 additional claims that were not challenged in the proceeding.

Why is the ’360 patent important to Seer (SEER)’s Proteograph platform?

The ’360 patent covers methods using engineered nano- and microparticles that form protein coronas to enrich proteins. These methods support Seer’s Proteograph Product Suite, enabling deep, unbiased proteomic analysis across a wide protein concentration range in biological samples.

Can Seer (SEER) or the petitioners appeal the PTAB’s decision?

Yes. Either Seer or the petitioners may appeal the PTAB’s Final Written Decision. A notice of appeal must be filed by May 25, 2026, which could lead to further review in the federal courts of specific patent claim rulings.

What broader intellectual property portfolio does Seer (SEER) report?

Seer states it has an intellectual property portfolio of more than 240 issued patents and pending patent applications worldwide. This includes 80 issued patents that, together with the ’360 patent, are described as supporting the Proteograph Product Suite and related technologies.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 10.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 29.7 KB